(Reuters) – Takeda Pharmaceutical Co Ltd ( 4502.T ) said Thursday the Japanese Fair Trade Commission has approved its acquisition of Shire Plc ( SHP.L) Approved $ 62 Billion ($ 47.3 Billion) ), the Japanese firm brings a degree that will make it a top 10 global pharmaceutical company.
FILE PHOTO: The Takeda Pharmaceutical Co logo will be on display in Tokyo on July 2, 2018. REUTERS / Kim Kyung-Hoon – RC1702FA7D40 / File Photo
The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional regulatory approvals in the United States, Brazil and China.
"Takeda is proud of its Japanese heritage, and we look forward to expanding that legacy as a combined company to continue to deliver highly innovative medicines that transform patients in Japan and around the world." Takeda CEO Christophe Weber said in a statement.
Takeda is also waiting for a nod from EU antitrust authorities. They are expected to make a decision by 6 November but may initiate a four-month investigation if they have serious concerns.
reporting by Takashi Umekawa in Tokyo and Shashwat Awasthi in Bengaluru; Editing by Sunil Nair